- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Biocon in collaboration with Equillium begins Itolizumab clinical study for Ulcerative Colitis in India
Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6- ALCAM pathway, which can drive several immuno-inflammatory diseases.
Bengaluru: Biocon Limited, an innovation-led global biopharmaceutical company, today announced the initiation of the clinical study of Itolizumab in patients with Ulcerative Colitis (UC) in India, in collaboration with Equillium Inc.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active UC. Having obtained approval from the Drugs Controller General of India (DCGI), the study will cover several tertiary hospitals specialized in handling UC cases. The first patient who intended to participate in the study was screened on December 1, 2022.
Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6- ALCAM pathway, which can drive several immuno-inflammatory diseases. This unique molecule holds the potential for multiple high-value indications. Biocon out-licensed Itolizumab to Equillium Inc. in 2017 to develop this molecule for the treatment of severe autoimmune and inflammatory disorders. The company is currently developing Itolizumab for acute graftversus-host-disease (aGVHD) and Lupus Nephritis.
Siddharth Mittal, Managing Director, and CEO, Biocon Limited, said, "We are encouraged by the progress being made on our high-value, multi-indication molecule, Itolizumab, in collaboration with Equillium. The commencement of the Phase two clinical study, that will determine its efficacy for the treatment of Ulcerative Colitis, is an important step forward in our efforts to bring its benefit to patients in India suffering from this disease. The development also underpins Biocon's commitment to bring innovative, affordable medicines, that address unmet patient needs, to market expeditiously."
Dr Sandeep Athalye, Chief Medical Officer, Biocon Biologics, added, "Among the developing regions of the world, India has the highest reported incidence of 9.31 cases per 100,000 persons for Inflammatory Bowel Disease and 5.41 cases per 100,000 persons for Ulcerative Colitis. Many of these cases do not respond to standard available therapy, such as corticosteroids, 5 Amino Salicylates (5- ASA), and immunosuppressive drugs, including TNF alfa inhibitors. We believe that Itolizumab can address this need for the treatment of UC, with better remission rates, more durable responses, and a better safety profile."
Commenting on the development, Dr Maple Fung, Senior Vice President of Clinical Development, Equillium Inc., said: "T cells play a pivotal role in the immune response that leads to Inflammatory Bowel Disease and preclinical models show a role for CD6 in disease pathogenesis. As Itolizumab has a novel dual mechanism of action that modulates both the activity and trafficking of CD6-expressing T effector cells, it is an ideal candidate for treatment of Ulcerative Colitis, where the severe inflammation can be debilitating. Additional supportive rationale can be found in our ongoing program investigating Itolizumab in severe acute graft-versus-host disease, where our Phase 1b EQUATE study demonstrated meaningful responses, particularly in those with lower gastroenterological symptoms."
Read also: Viatris sells global biosimilars business to Biocon Biologics for USD 3 billion
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751